Multivitamin Biological Clock Study after two-year trial points to modest slowing of epigenetic aging

The multivitamin biological clock study, a two-year randomized ancillary analysis of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), found that daily multivitamin use produced a small but measurable slowing of some DNA methylation–based measures of biological ageing in older adults.

What Happens When the trial’s design and results are examined?

The trial analysed 958 generally healthy older adults with an average chronological age of about 70. Participants were randomly assigned to four pill regimens: multivitamin with cocoa extract, multivitamin with cocoa placebo, cocoa extract with multivitamin placebo, or two placebos. Blood samples taken at baseline, one year and two years were tested on five epigenetic clocks (PCHannum, PCHorvath, PCPhenoAge, PCGrimAge and DunedinPACE).

The pre-specified ancillary analysis, published in Nature Medicine and drawing on COSMOS data, found that daily multivitamin–multimineral supplementation modestly reduced the rate of increase for two second‑generation clocks used to estimate mortality risk: PCGrimAge and PCPhenoAge. Across the two-year period the effect equated to roughly four months less biological ageing overall. Cocoa extract showed no effect on any of the five clocks and did not interact with the multivitamin intervention.

Howard Sesso, associate director of preventive medicine at Brigham and Women’s Hospital and Harvard Medical School and senior author of the study, emphasised that the findings do not mean all older adults must begin taking a multivitamin and that the clinical relevance of the epigenetic changes remains to be established. The trial team noted that participants with accelerated biological ageing at baseline experienced a larger benefit, suggesting nutritional status or baseline deficits may partly explain the pattern.

What Happens When the Multivitamin Biological Clock Study findings are placed in context?

The COSMOS ancillary results are statistically significant but small in magnitude, and the authors call for further research to determine whether the modest epigenetic shifts translate into meaningful health outcomes. The study used validated methylation measures and randomization, strengthening causal interpretation for the molecular endpoints tested, yet the connection from epigenetic-clock slowing to concrete clinical benefits was not established by this analysis.

Daniel Belsky, associate professor of epidemiology at the Robert N. Butler Columbia Aging Center, has emphasised the broader measurement challenge in the field: “there is no gold standard measurement of aging. ” That uncertainty matters here—different clocks capture different aging biology and some are better correlated with specific outcomes than others. The COSMOS ancillary work found signal in the two second‑generation clocks (PCGrimAge and PCPhenoAge) that index mortality-related biology, while the other clocks showed no consistent change.

What Happens Next — how should clinicians, researchers and older adults respond?

• Key trial facts: 958 participants, two-year intervention, five epigenetic clocks tested, measurable slowing on PCGrimAge and PCPhenoAge, no effect of cocoa extract.
• Magnitude and meaning: roughly four months less biological ageing over two years overall; larger effects for those with accelerated baseline ageing; clinical implications unresolved.
• Research priorities: replication in other cohorts, linking epigenetic changes to hard clinical endpoints, and parsing which subgroups derive meaningful benefit.

Practical guidance anchored to the study: the trial authors noted no known risks from daily multivitamin use in their larger clinical program, but they also cautioned that who benefits and by how much remains unclear. Sesso urged individual decision‑making in consultation with a health care provider. Meanwhile, the scientific community should treat these molecular results as hypothesis‑generating—encouraging targeted follow‑ups rather than immediate broad changes in clinical practice.

Readers should understand that the COSMOS ancillary analysis strengthens the evidence that daily multivitamin–multimineral supplementation can nudge some epigenetic measures of ageing in older adults, but it does not prove a change in lifespan or major disease risk. The cautious, evidence‑driven next steps will be replication, mechanistic work, and trials that tie molecular shifts to clinical outcomes. Those considerations are the pragmatic takeaways from the multivitamin biological clock study